This event requires pre-registration.
The March 10th Bio2Device Group Meeting has been canceled at Wilson Sonsini.
Please see notice below–
Wilson Sonsini Goodrich & Rosati is committed to contributing to the global, national, and local efforts to contain and slow the spread of the virus. As such, we are taking precautionary measures and will not be hosting group gatherings in our offices until further notice. To that end, we will need to cancel the Bio2Device event being held on March 10 in our Palo Alto office.
We will keep you abreast of any future changes in schedule or presentation mode.
This event is generously supported by and hosted at our sponsor: Wilson Sonsini Goodrich & Rosati
Event Information
Event Topic:
THIS EVENT HAS BEEN CANCELED- It will be rescheduled for October 13; for full event information check out the complete event listing
Event Description:
The discovery of CRISPR/Cas9 opened a new era of gene editing for research and therapeutic use. Gene editing tools including zinc finger nucleases, Cas9, Cas12a, and base editors have shown their potential to enable new approaches in curing genetic and non-genetic disorders. In my presentation, I will introduce recent approaches in gene therapy and gene editing and new innovations in the field of non-viral vector gene delivery. The use of non-viral delivery of CRISPR ribonucleoproteins (RNPs) using polymer nanoparticles in Duchenne muscular dystrophy and Fragile X syndrome mouse models will be presented. I will also discuss the challenges of translating broader gene therapy into the clinic and new approaches to overcome the challenges. Lastly, I will share my thoughts on the changes in the startup ecosystem and my story of founding a new startup company in the Bay Area.
Date/Time:
Date(s) - 03/10/20
6:00 pm - 9:00 pm
Event Location:
Wilson Sonsini Goodrich & Rosati – 650 Page Mill Rd, Palo Alto:
Speaker Information
Event Speaker:
Kunwoo Lee
Event Speaker Title:
CEO & Founder
Event Speaker Company:
GenEdit
Event Speaker Bio:
Dr. Kunwoo Lee is the Co-Founder and CEO of GenEdit. He received a PhD from UC Berkeley/UCSF in the Department of Bioengineering. He has always had a passion for technology innovation changing people’s lives and it led him to involve in CRISPR revolution. He is the inventor of several delivery technologies for CRISPR/Cas9, which have shown great potential to revolutionize the treatment of genetic disorders. He was named as a Forbes 30 under 30 in 2017 and was a Siebel Scholar in 2016.
Event Details
Cost:
Early-bird Members: $15 or $10 if student or in transition; General Public: $20; Walk-in: $30 if space permits
Add To Calendar
